Fosravuconazole

Fosravuconazole (trade name Nailin) is a triazole antifungal agent.[1][2] In Japan, it is approved for the treatment of onychomycosis, a fungal infection of the nail.[3] It is a prodrug that is converted into ravuconazole.[1]

Fosravuconazole
Clinical data
Trade namesNailin
Other namesBMS-379224; BFE-1224; E-1224
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
  • [(2R,3R)-3-[4-(4-Cyanophenyl)-1,3-thiazol-2-yl]-2-(2,4-difluorophenyl)-1-(1,2,4-triazol-1-yl)butan-2-yl]oxymethyl dihydrogen phosphate
CAS Number
PubChem CID
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC23H20F2N5O5PS
Molar mass547.47 g·mol−1
3D model (JSmol)
  • C[C@@H](c1nc(-c2ccc(C#N)cc2)cs1)[C@@](Cn1cncn1)(OCOP(=O)(O)O)c1ccc(F)cc1F
  • InChI=1S/C23H20F2N5O5PS/c1-15(22-29-21(10-37-22)17-4-2-16(9-26)3-5-17)23(11-30-13-27-12-28-30,34-14-35-36(31,32)33)19-7-6-18(24)8-20(19)25/h2-8,10,12-13,15H,11,14H2,1H3,(H2,31,32,33)/t15-,23+/m0/s1
  • Key:SYTNEMZCCLUTNX-NPMXOYFQSA-N

The Drugs for Neglected Diseases Initiative and the Japanese pharmaceutical company Eisai are studying fosravuconazole as a potential treatment for eumycetoma.[1][4][5]

References
  1. Yamaguchi H (2016). "Potential of Ravuconazole and its Prodrugs as the New OralTherapeutics for Onychomycosis". Medical Mycology Journal. 57 (4): E93–E110. doi:10.3314/mmj.16-00006. PMID 27904057.
  2. "Fosravuconazole - Seren Pharmaceuticals". Adis Insight. Springer Nature Switzerland AG.
  3. "Oral Antifungal Agent Nailin Capsules 100 mg Approved in Japan" (Press release). Eisai. January 19, 2018.
  4. "Fosravuconazole". Drugs for Neglected Diseases Initiative.
  5. "Drugs for Neglected Diseases initiative and Eisai Co., Ltd. to Test Drug Candidate for Eumycetoma | News Release：2015 | Eisai Co., Ltd". www.eisai.com. Retrieved 2020-08-14.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.